亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688176 亚虹医药

已收盘 01-21 15:00:00

{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":6.61,"timestamp":1737442800000,"preClose":6.73,"halted":0,"volume":2881497,"delay":0,"changeRate":-0.0178,"floatShares":378000000,"shares":570000000,"eps":-0.7075,"marketStatus":"已收盘","change":-0.12,"latestTime":"01-21 15:00:00","open":6.73,"high":6.75,"low":6.58,"amount":19142300,"amplitude":0.0253,"askPrice":6.62,"askSize":213,"bidPrice":6.61,"bidSize":852,"shortable":0,"etf":0,"ttmEps":-0.7075,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1737509400000},"marketStatusCode":5,"adr":0,"adjPreClose":6.73,"symbolType":"stock_kcb","openAndCloseTimeList":[[1737423000000,1737430200000],[1737435600000,1737442800000]],"highLimit":7.4,"lowLimit":6.06,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":570000000,"isCdr":false,"pbRate":1.81,"roa":"--","roe":"--","epsLYR":-0.7,"committee":0.02167,"marketValue":3768000000,"turnoverRate":0.0076,"status":1,"afterMarket":{"amount":0,"volume":0,"close":6.61,"buyVolume":0,"sellVolume":0,"time":1737444838029,"indexStatus":"已收盘 01-21 15:30:00","preClose":6.73},"floatMarketCap":2500000000},"requestUrl":"/m/hq/s/688176/tweets","defaultTab":"tweets","newsList":[{"id":"2504132548","title":"亚虹医药(688176.SH)发预亏，预计2024年度净亏损4.37亿元到3.66亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504132548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504132548?lang=zh_cn&edition=full","pubTime":"2025-01-17 18:14","pubTimestamp":1737108879,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布2024年年度业绩预告，公司预计2024年度实现归属于母公司所有者的净亏损4.37亿元到3.66亿元;预计2024年度归属于母公司所有者扣除非经常性损益后的净亏损4.65亿元到3.89亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1239520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2504139250","title":"亚虹医药：预计2024年净利润亏损4.37亿元到3.66亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504139250","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504139250?lang=zh_cn&edition=full","pubTime":"2025-01-17 17:31","pubTimestamp":1737106260,"startTime":"0","endTime":"0","summary":"亚虹医药公告，预计2024年度实现归属于母公司所有者的净利润为-4.37亿元到-3.66亿元，与上年同期相比，净利润增加-3648.39万元到3436.77万元。预计2024年度研发费用约2.97亿元到3.54亿元，比上年同期减少6769.55万元到1023.17万元，同比减少18.57%到2.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011717314496073072&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011717314496073072&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176"],"gpt_icon":0},{"id":"2504133189","title":"亚虹医药：公司用于膀胱癌检查和随访的显影剂产品APL-1706（灌注用盐酸氨酮戊酸己酯）已于2024年11月收到国家药品监督管理局核准签发的《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2504133189","media":"互动易","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504133189?lang=zh_cn&edition=full","pubTime":"2025-01-17 16:30","pubTimestamp":1737102600,"startTime":"0","endTime":"0","summary":"有投资者向亚虹医药提问， 董秘，好！请回答，谢谢公司回答表示，尊敬的投资者，您好！公司用于膀胱癌检查和随访的显影剂产品APL-1706已于2024年11月收到国家药品监督管理局核准签发的《药品注册证书》。国内尚无蓝光膀胱镜获批上市，当前已知国内进度较快的蓝光膀胱镜的上市申请已于2024年下半年获得受理，目前尚在审评审批中。同时，公司针对美国诊所市场的使用场景和需求，合作开发的便携式一次性诊断用蓝光膀胱软镜APLD-2304尚在研发中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117163603abae4aa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117163603abae4aa0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2504133184","title":"亚虹医药：目前公司未触及财务类强制退市情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2504133184","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504133184?lang=zh_cn&edition=full","pubTime":"2025-01-17 16:30","pubTimestamp":1737102600,"startTime":"0","endTime":"0","summary":"有投资者向亚虹医药提问， 董秘你好，请问公司连续亏损， 公司有没有被强制退市或ST的可能？公司回答表示，尊敬的投资者，您好！公司为科创板第五套标准上市的公司，于2022年1月7日在上交所科创板上市。根据《上海证券交易所科创板股票上市规则》12.4.2.条规定，第五套标准上市的公司自上市之日起第4个完整会计年度起适用相关退市财务指标。目前公司未触及财务类强制退市情形。感谢您的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117163554abae4a90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117163554abae4a90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2503395213","title":"亚虹医药(688176.SH)：APL-2302临床试验申请获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2503395213","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503395213?lang=zh_cn&edition=full","pubTime":"2025-01-16 16:52","pubTimestamp":1737017536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，近日，公司收到国家药品监督管理局(NMPA)签发的《药物临床试验批准通知书》，公司自主研发的APL2302(ASN-3186胶囊)获得国家药品监督管理局的临床试验批准，计划针对晚期实体瘤开展临床试验。本次APL-2302临床试验申请获得NMPA批准事项对公司近期业绩不会产生重大影响。由于药品的研发周期长、审批环节多、研发投入大，容易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1238666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239","03347","BK1576","BK1141","BK1583"],"gpt_icon":0},{"id":"2503526389","title":"亚虹医药：APL-2302临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2503526389","media":"财通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503526389?lang=zh_cn&edition=full","pubTime":"2025-01-16 16:41","pubTimestamp":1737016860,"startTime":"0","endTime":"0","summary":"亚虹医药公告，公司自主研发的APL-2302（ASN-3186胶囊）获得国家药品监督管理局的临床试验批准，计划针对晚期实体瘤开展临床试验。APL-2302是一种泛素特异性蛋白酶1（USP1）抑制剂，通过“合成致死”机制发挥抗肿瘤作用。临床前研究提示APL-2302单药治疗和联合治疗在肿瘤抑制方面表现出良好的体外和体内活性，有潜力成为治疗特定生物标志物阳性（如BRCA基因突变等）的晚期实体瘤（乳腺癌、卵巢癌、前列腺癌等）的新选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501161642299868364a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501161642299868364a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2503027893","title":"国家医保局将出台新举措支持创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2503027893","media":"新华社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503027893?lang=zh_cn&edition=full","pubTime":"2025-01-13 19:58","pubTimestamp":1736769480,"startTime":"0","endTime":"0","summary":"据了解，国家医保局日前召开支持创新药发展企业座谈会，与部分医药企业交流创新药发展情况，听取对医保部门支持创新药发展的意见建议。国家医保局有关负责人此前表示，要在坚持基本医保“保基本”的前提下，将更多新药好药纳入医保目录，真支持创新、支持真创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011319591096022f17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011319591096022f17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600422","603367","688176","BK0028","BK0239","BK0188","159992","BK0060"],"gpt_icon":0},{"id":"2502185675","title":"亚虹医药：大岩资本、明道私募等多家机构于1月10日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2502185675","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502185675?lang=zh_cn&edition=full","pubTime":"2025-01-10 19:01","pubTimestamp":1736506919,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年1月10日亚虹医药发布公告称大岩资本、明道私募、天风资管、汉鸿基金、财通资本、东北证券、澜胜私募、畅力资产于2025年1月10日调研我司。目前宫颈高级别病变的治疗仍以有创性宫颈切除术为主。因此，宫颈癌前病变需要长期的监测管理，手术治疗后仍要持续随访10至25年。该股最近90天内共有1家机构给出评级，买入评级1家；过去90天内机构目标均价为9.6。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011000036051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2502832248","title":"【亚虹医药：APL-1702有望填补宫颈病变治疗空白】金融界1月10日消息，亚虹医药披露投资者关系活动记录表显示APL-1702有望填补宫颈高级别鳞状上皮内病变治疗的巨大空白地带，让患者在逆转病程的同时，最大程度避免或延缓宫颈切除手术带来的风险，并重新定义宫颈癌前病变的治疗目标，使治疗聚焦于疾病的长期管理，平衡治疗风险与收益。","url":"https://stock-news.laohu8.com/highlight/detail?id=2502832248","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502832248?lang=zh_cn&edition=full","pubTime":"2025-01-10 17:37","pubTimestamp":1736501855,"startTime":"0","endTime":"0","summary":"金融界1月10日消息，亚虹医药披露投资者关系活动记录表显示APL-1702有望填补宫颈高级别鳞状上皮内病变治疗的巨大空白地带，让患者在逆转病程的同时，最大程度避免或延缓宫颈切除手术带来的风险，并重新定义宫颈癌前病变的治疗目标，使治疗聚焦于疾病的长期管理，平衡治疗风险与收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/10173747343759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2501292400","title":"亚虹医药（688176）680.05万股限售股将于1月7日解禁，占总股本1.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501292400","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501292400?lang=zh_cn&edition=full","pubTime":"2025-01-07 08:04","pubTimestamp":1736208255,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，亚虹医药于1月7日将有680.05万股限售股份解禁，为公司首发原股东限售股份，占公司总股本1.19%。最近一年内，该股累计解禁330.0万股，占总股本的0.58%。本次解禁后，公司还有1.92亿股限售股份，占总股本33.63%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010700007682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2501229454","title":"1.99亿元市值限售股今日解禁，厦门钨业、亚虹医药-U、芯原股份解禁市值居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2501229454","media":"界面","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501229454?lang=zh_cn&edition=full","pubTime":"2025-01-07 07:43","pubTimestamp":1736206984,"startTime":"0","endTime":"0","summary":"Wind数据显示，周二（1月7日），共有7家公司限售股解禁，合计解禁量为1481.97万股，按最新收盘价计算，合计解禁市值为1.99亿元。从解禁量来看，亚虹医药-U、厦门钨业、必得科技解禁量居前，解禁股数分别为680.05万股、335.82万股、213.2万股。从解禁市值来看，厦门钨业、亚虹医药-U、芯原股份解禁市值居前，解禁市值分别为6400.73万元、4481.5万元、3225.42万元。从解禁股数占总股本比例来看，亚虹医药-U、必得科技、英诺激光解禁比例居前，解禁比例分别为1.19%、1.13%、0.42%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010707430495fad3dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010707430495fad3dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","688521","BK0182","BK0239","BK0233","BK0231","BK0084","BK0028","688176","600549","BK0155"],"gpt_icon":0},{"id":"2501825832","title":"亚虹医药与美国CDC签署药物拓展性研究项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2501825832","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501825832?lang=zh_cn&edition=full","pubTime":"2025-01-06 18:57","pubTimestamp":1736161020,"startTime":"0","endTime":"0","summary":"南方财经1月6日电，亚虹医药 近日宣布，就其自主研发的APL-1202与美国疾病控制与预防中心共同签署了药物拓展性研究项目下的研究用药供应协议，经CDC专家评估适用的前提下，用于治疗自由生活阿米巴感染。CDC向FDA提交了拓展性临床研究申请，以提供APL-1202用于治疗实验室确认或疑似非角膜炎感染引起的FLA，包括上述三种阿米巴感染。协议签署后，亚虹医药已及时安排药物运输，以保障FLA患者的临床供药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010618593195fa3c77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010618593195fa3c77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2500319682","title":"国办：审评审批资源向临床急需重点创新药和医疗器械倾斜","url":"https://stock-news.laohu8.com/highlight/detail?id=2500319682","media":"北京商报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500319682?lang=zh_cn&edition=full","pubTime":"2025-01-03 18:49","pubTimestamp":1735901344,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 王寅浩）1月3日，国务院办公厅发布《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（以下简称《意见》）。《意见》提出，要完善审评审批机制全力支持重大创新。按照“提前介入、一企一策、全程指导、研审联动”要求，审评审批资源更多向临床急需的重点创新药和医疗器械倾斜，在临床试验、注册申报、核查检验、审评审批等全过程加强沟通交流，提供个性化指导。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318490695f7a94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318490695f7a94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688278","688067","688212","688358","688520","159883","688606","600829","688314","688192","688578","688131","159992","688621","688382","688075","600080","603976","601089","688607","603590","688468","688176","688656","688580","603301","688687","688710","BK0239","603733","600763","603205","688331","688161","688575","603087","688166","605369","688050","688338","600998","688302","688389","688289","688799","600135","603987","688356","BK0251","688013","688767","603583","688193"],"gpt_icon":0},{"id":"2494877068","title":"亚虹医药(688176.SH)约680.05万股限售股将于1月7日起上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2494877068","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494877068?lang=zh_cn&edition=full","pubTime":"2024-12-27 18:02","pubTimestamp":1735293738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，本次上市流通的限售股为公司首次公开发行前部分限售股，涉及的限售股股东数量为1名，锁定期为自公司首次公开发行上市之日起36个月，该部分限售股股东对应的股份数量约为680.05万股，占公司股本总数的1.19%，现锁定期即将届满，将于2025年1月7日起上市流通。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1230148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2494872218","title":"亚虹医药：股东自愿承诺延长股份锁定期","url":"https://stock-news.laohu8.com/highlight/detail?id=2494872218","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494872218?lang=zh_cn&edition=full","pubTime":"2024-12-27 17:44","pubTimestamp":1735292663,"startTime":"0","endTime":"0","summary":"格隆汇12月27日丨亚虹医药公布，近日收到公司股东出具的《关于自愿延长限售股锁定期的承诺函》。在上述承诺锁定期内，因公司送红股、转增股本、配股等原因而增加的股份，亦将遵守上述延长锁定期的承诺。上述3名股东在所持股份于2025年7月7日上市流通后，仍需严格遵守《上市公司股东减持股份管理暂行办法》或届时适用的法律、法规、规范性文件或监管部门、证券交易所关于减持股份的相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227174423985176b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227174423985176b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2494872297","title":"亚虹医药：已实际回购1.5206%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2494872297","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494872297?lang=zh_cn&edition=full","pubTime":"2024-12-27 17:43","pubTimestamp":1735292629,"startTime":"0","endTime":"0","summary":"格隆汇12月27日丨亚虹医药(688176.SH)公布，2024年12月26日，公司完成回购，已实际回购公司股份8,667,675股，占公司总股本的比例为1.5206%，回购最高价格为7.07元/股，回购最低价格为4.99元/股，回购均价为5.77元/股，支付的资金总额为人民币5,001.85万元（不含印花税、交易佣金等交易费用）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227174349a20ba9ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227174349a20ba9ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2494839482","title":"亚虹医药-U12月26日主力资金流出14万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2494839482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494839482?lang=zh_cn&edition=full","pubTime":"2024-12-26 15:19","pubTimestamp":1735197570,"startTime":"0","endTime":"0","summary":"12月26日，亚虹医药-U股价收平报7.05元，成交金额2238万元，换手率0.86%，振幅1.13%，量比0.67。亚虹医药-U今日主力资金净流出14万元，连续3日净流出，上一交易日主力净流出932万元，今日环比减少98.50%。该股近5个交易日下跌2.89%，主力资金累计净流出1855万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出3403万元，其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226152753ab930dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226152753ab930dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2493083023","title":"亚虹医药收盘下跌1.40%，最新市净率1.93","url":"https://stock-news.laohu8.com/highlight/detail?id=2493083023","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493083023?lang=zh_cn&edition=full","pubTime":"2024-12-24 20:26","pubTimestamp":1735043191,"startTime":"0","endTime":"0","summary":"12月24日，亚虹医药今日收盘7.04元，下跌1.40%，最新市净率1.93。消息面上，亚虹医药11月19日接待投资者等1家机构调研，上市公司接待人员包括董事长、总经理PANKE,董事、董事会秘书、财务负责人杨明远,独立董事黄彬。江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及其它重大疾病领域创新药的研发、生产和销售。最新一期业绩显示，2024年三季报，公司实现营业收入1.39亿元，同比4537.79%；净利润-270840063.46元，同比-1.04%，销售毛利率79.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224202935984d63e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224202935984d63e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2492485644","title":"亚虹医药收盘上涨0.96%，最新市净率2.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2492485644","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492485644?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:47","pubTimestamp":1734698844,"startTime":"0","endTime":"0","summary":"12月20日，亚虹医药今日收盘7.33元，上涨0.96%，最新市净率2.01。股东方面，截至2024年9月30日，亚虹医药股东户数27825户，较上次减少802户，户均持股市值35.28万元，户均持股数量2.76万股。江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及其它重大疾病领域创新药的研发、生产和销售。最新一期业绩显示，2024年三季报，公司实现营业收入1.39亿元，同比4537.79%；净利润-270840063.46元，同比-1.04%，销售毛利率79.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205132ab872408&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220205132ab872408&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688315","600329","688189","688321","600196","600285","603233","600566","688073","688331","688161","600080","603392","605177","688389","600521","688617","603538","600511","688062","600200","600436","600739","600422","688193","688076","600332","159938","603439","603301","600351","600420","688670","688767","688581","688626","688298","688382","688114","688180","BK0012","688301","603939","688356","688067","600763","688488","688202","688266","600062","688373","688139","688428","600867","600276","600572","BK0188","603108","688235","688192","600488","BK0239","688247","688271","600380","688336","688687","600161","603658","603367","605199","600056","601607","600252","688085","600085","600721","603882","600851","600976","688177","603087","688276","603590","688578","688137","BK0028","603858","603707","600055","688050","688690","688105","688198","600529","688176","600535","688222","600771","603567","600211","688166","603309","688091","BK0185","688351","688566","600129","603127","688278","688658","603896","688117","BK0096","600079","603259","688221","BK0070","688656","688575","688029","688520","603456","688212","688443","688506","688046","600998","688163"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","stockEarnings":[{"period":"1week","weight":0.0402},{"period":"1month","weight":-0.0819},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.3541},{"period":"1year","weight":-0.2352},{"period":"ytd","weight":-0.0088}],"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","perCapita":"13595股","boardName":"医药制造业","registeredCapital":"57000万元","compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0367},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.118},{"period":"1year","weight":0.1455},{"period":"ytd","weight":-0.032}],"survey":"　　江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统（UrogenitalSystem）肿瘤及其它重大疾病领域创新药的研发、生产和销售。公司的主要产品是APL-1702、APL-1202、APL-1501(第二代APL-1202)、APL-1706、APLD-2304、AT-014、AT-020、APL-2302、AT-017、AT-018、AT-021、APL-1401、APL-2301。","serverTime":1737452590692,"listedPrice":22.98,"stockholders":"27825人(较上一季度减少2.80%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}